Invuity, Inc., a medical technology company, develops and markets surgical devices in the United States and Asia. The company through its intelligent photonics technology platform develops single-use and reusable illuminated surgical devices, which provide surgeons with illumination and direct visualization of surgical cavities. It offers various illuminated surgical devices, including Eikon LT illuminated retractor system for breast/oncoplastic/gynecology/EP/plastic/endocrine surgeries; Eiberg illuminated retractor systems for orthopedic surgeries; PhotonBlade, a recision illuminator for breast/plastics/EP/orthopedics surgeries; PhotonSaber Y, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general/gynecology/plastic surgeries; and PhotonSaber F, a handheld illuminator for spine/orthopedic/neurosurgery surgeries. The company also provides Breiten illuminated retractor systems for spine/orthopedic surgeries; Photonguide XT system, a drop-in intracavity illuminator for spine surgeries; Eika illuminated retractor systems for endocrine/spine/orthopedic surgeries; and PhotonVue, a system used in conjunction with IC Indocyanine for identifying and verifying blood flow in tissue, as well as is used in breast/plastic/colorectal surgeries. It sells its devices through direct sales representatives and independent sales agents; and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. The company was formerly known as Spotlight Surgical, Inc. and changed its name to Invuity, Inc. in 2007. Invuity, Inc. was incorporated in 2004 and is based in San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IVTY
CUSIPN/A
Phone415-655-2100
Debt
Debt-to-Equity Ratio10.57
Current Ratio2.13
Quick Ratio1.69
Price-To-Earnings
Trailing P/E Ratio-3.36
Forward P/E Ratio-5.25
P/E GrowthN/A
Sales & Book Value
Annual Sales$39.62 million
Price / Sales4.50
Cash FlowN/A
Price / CashN/A
Book Value($0.05) per share
Price / Book-148.00
Profitability
EPS (Most Recent Fiscal Year)($2.20)
Net Income$-39,910,000.00
Net Margins-89.29%
Return on Equity-724.87%
Return on Assets-70.87%
Miscellaneous
Employees161
Outstanding Shares24,070,000
Market Cap$178.15 million
Invuity (NASDAQ:IVTY) Frequently Asked Questions
What is Invuity's stock symbol?
Invuity trades on the NASDAQ under the ticker symbol "IVTY."
How were Invuity's earnings last quarter?
Invuity Inc (NASDAQ:IVTY) released its quarterly earnings data on Thursday, August, 2nd. The medical instruments supplier reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.47) by $0.10. The medical instruments supplier had revenue of $10.50 million for the quarter, compared to the consensus estimate of $10.73 million. Invuity had a negative return on equity of 724.87% and a negative net margin of 89.29%. View Invuity's Earnings History.
When is Invuity's next earnings date?
What price target have analysts set for IVTY?
5 brokerages have issued 12-month price objectives for Invuity's stock. Their predictions range from $5.00 to $12.00. On average, they anticipate Invuity's stock price to reach $7.6667 in the next twelve months. This suggests a possible upside of 3.6% from the stock's current price. View Analyst Price Targets for Invuity.
What is the consensus analysts' recommendation for Invuity?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invuity in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Invuity.
What are Wall Street analysts saying about Invuity stock?
Here are some recent quotes from research analysts about Invuity stock:
- 1. According to Zacks Investment Research, "Invuity, Inc. is a medical technology company. Its products include Eikon Illuminated Retractor System, Saber Yankauer, Saber Frazier, Eika Illuminated Retractor System, Breiten Illuminated Retractor System, Eipex Illuminated Retractor System, Eivector Illuminated Retractor System and Waveguide XT System. The Company sells its devices through its direct sales representatives and original equipment manufacturers of surgical systems. Invuity, Inc. is based in San Francisco, California. " (7/5/2018)
- 2. Northland Securities analysts commented, "We would be remiss in not expressing our disappointment, and are lowering our PT to $6." (2/14/2018)
Are investors shorting Invuity?
Invuity saw a decrease in short interest during the month of September. As of September 28th, there was short interest totalling 157,848 shares, a decrease of 76.6% from the September 14th total of 674,048 shares. Based on an average trading volume of 452,141 shares, the short-interest ratio is presently 0.3 days. Approximately 0.8% of the shares of the company are sold short. View Invuity's Current Options Chain.
Who are some of Invuity's key competitors?
Some companies that are related to Invuity include Anika Therapeutics (ANIK), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), Inovio Pharmaceuticals (INO), Liquidia Technologies (LQDA), Orthopediatrics (KIDS), Neuronetics (STIM), GenMark Diagnostics (GNMK), Westaim (WEDXF), Cytosorbents (CTSO), Utah Medical Products (UTMD), Accuray (ARAY), Nuvectra (NVTR) and Iradimed (IRMD).
Who are Invuity's key executives?
Invuity's management team includes the folowing people:
- Mr. Scott D. Flora, Interim Pres, CEO & Director (Age 62)
- Mr. Philip M. Sawyer, CEO, Pres & Director (Age 53)
- Mr. James H. MacKaness, Chief Financial Officer (Age 54)
- Mr. Douglas W. Heigel, Sr. VP of Operations (Age 57)
- Ms. Marcia Fish, Chief HR Officer (Age 54)
When did Invuity IPO?
(IVTY) raised $48 million in an IPO on the week of June 15th 2015. The company issued 4,000,000 shares at a price of $12.00 per share. Piper Jaffray, Leerink Partners and Stifel served as the underwriters for the IPO and William Blair was co-manager.
Who are Invuity's major shareholders?
Invuity's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Kassirer Asset Management Corp (2.32%). Company insiders that own Invuity stock include Andrew Sale, Eric W Roberts, Gregory T Lucier, James E Flynn, James H Mackaness, Marcia Fish, Reza Zadno and Scott D Flora. View Institutional Ownership Trends for Invuity.
Which major investors are buying Invuity stock?
IVTY stock was purchased by a variety of institutional investors in the last quarter, including Kassirer Asset Management Corp. Company insiders that have bought Invuity stock in the last two years include Andrew Sale, Eric W Roberts, Gregory T Lucier, James H Mackaness, Marcia Fish and Scott D Flora. View Insider Buying and Selling for Invuity.
How do I buy shares of Invuity?
Shares of IVTY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Invuity's stock price today?
One share of IVTY stock can currently be purchased for approximately $7.40.
How big of a company is Invuity?
Invuity has a market capitalization of $178.15 million and generates $39.62 million in revenue each year. The medical instruments supplier earns $-39,910,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Invuity employs 161 workers across the globe.
What is Invuity's official website?
How can I contact Invuity?
Invuity's mailing address is 444 DE HARO STREET, San Francisco CA, 94107. The medical instruments supplier can be reached via phone at 415-655-2100 or via email at [email protected]
MarketBeat Community Rating for Invuity (NASDAQ IVTY)
MarketBeat's community ratings are surveys of what our community members think about Invuity and other stocks. Vote "Outperform" if you believe IVTY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IVTY will underperform the S&P 500 over the long term. You may vote once every thirty days.
